nmdp logo

Panel: mismatched unrelated donor HCT


This panel discussion will provide insight into the 15-MMUD study that looks at mismatched unrelated donor (MMUD) HCT using PTCy and bone marrow. The results show it is safe and effective, expanding access for diverse populations. The panelists will discuss implications of this study on the BMT and CGT field and how it could impact clinical decision-making on patient treatment.

On-demand panel discussion link

Learning Objectives

  • The results of the Access study/15-MMUD study (PTCY and bone marrow)
  • The ongoing efforts to determine efficacy of PTCY and PBSC
  • Considerations between haploidentical donors and mismatched unrelated donors
  • Implications of these studies to the field of BMT and CGT: How these learnings impact clinical decision-making for patients of underserved populations; what barriers to transplant might still exist, despite improving treatment outcomes


  • Steven Devine, MD, Chief Medical Officer, NMDP, Associate Scientific Director, CIBMTR
  • Gary Simmons, DO, Virginia Commonwealth University Medical Center
  • Krishna Komanduri, MD, University of Miami